12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

EryDex: Phase II data

An open-label, Italian Phase II trial in 22 patients with genetically-confirmed ataxia telangiectasia showed that monthly EryDex encapsulated in autologous erythrocytes met the primary endpoint of reducing total ICARS score from baseline to 6 months (p=0.02). EryDex also met the secondary endpoint of improving VABS total score...

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >